Gecko Biomedical (“Gecko”), a medical device company developing innovative polymers to support tissue healing, has closed a €22.5 million financing round. This round was led by Sofinnova Partners with Bpifrance and existing investors Omnes Capital, CM-CIC Innovation and CapDecisif Management, who invested in the company in December 2013.
The funds raised will be used to further advance the development of Gecko’s first platform GB-02 for cardiovascular reconstruction and beyond. In addition, the funds will be used to leverage its fully industrialized platform in novel areas including guided tissue repair and localized drug delivery.
Gecko’s platform has demonstrated its ability to be fully industrialized, with a unique level of biocompatibility and a great potential in terms of versatility.
This platform is based on proprietary polymers with unique chemical and physical properties, including high viscosity, hydrophobicity and fast “on demand” curing for precise local delivery and in situ adhesion. Upon curing, an elastic biodegradable film is formed. The structure of the polymer is tunable, allowing customization for various applications and tissues.